SS

Stephen Schmitz

Vice President, Pharmacovigilance at Dragonfly Therapeutics

Stephen Schmitz, MD, MPH, possesses extensive experience in the field of pharmacovigilance and medical safety. Currently serving as the Vice President of Pharmacovigilance at Dragonfly Therapeutics, Inc., Stephen previously held the position of Chief Medical Officer at Ur24Technology, Inc. Additionally, Stephen has worked as Vice-President of Global Medical Safety at Kiniksa Pharmaceuticals and as Vice-President of Pharmacovigilance and Risk Management at Wave Life Sciences.

Links


Org chart

No direct reports

Teams

This person is not in any teams


Offices

This person is not in any offices


Dragonfly Therapeutics

1 followers

Dragonfly Therapeutics is a discovery-stage company developing drugs to stimulate immune responses against cancer.


Industries

Employees

51-200

Links